Werewolf Therapeutics (HOWL) EBITDA Margin (2022 - 2026)

Werewolf Therapeutics (HOWL) has reported EBITDA Margin for 4 consecutive years, with 34.09% the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA Margin changed N/A year-over-year to 34.09% in Q2 2026; TTM through Jun 2026 was 148.84%, a 48655116.0% increase from a year earlier, with the FY2024 full-year figure at 3873.37%, down 367027.0% from the prior year.
• EBITDA Margin was 34.09% for Q2 2026 at Werewolf Therapeutics, up from 135653.33% in the prior quarter.
• Over five years, EBITDA Margin peaked at 34.09% in Q2 2026 and troughed at 135653.33% in Q4 2024.
• A 4-year average of 12886.77% and a median of 273.81% in 2023 frame the typical range for EBITDA Margin.
• Across the five-year window, EBITDA Margin jumped 28587 bps in 2023 and slumped 13478978 bps in 2024, its largest moves.
• Over 4 years, EBITDA Margin stood at 180.96% in 2022, then plunged by 377 bps to 863.56% in 2023, then slumped by 15609 bps to 135653.33% in 2024, then jumped by 100 bps to 34.09% in 2026.
• The last three EBITDA Margin figures came in at 34.09% (Q2 2026), 135653.33% (Q4 2024), and 1658.79% (Q2 2024), per Business Quant data.